Anteris Announces Results for the First Quarter of 2026

Anteris Technologies reported Q1 2026 results with $320 million in capital raises completed to support the PARADIGM Trial for its DurAVR® THV System. The company achieved U.S. patient enrollment commencement post-quarter and secured CMS reimbursement coverage, facilitating U.S. site activation. Net operating cash outflows were $28.7 million, primarily driven by clinical, regulatory, and manufacturing activities.

05/12/2026, 7:00 PM • GlobeNewswire

Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial

Anteris Technologies announced it has secured U.S. Medicare reimbursement eligibility for its PARADIGM Trial under a Coverage with Evidence Development model. The trial will evaluate the safety and effectiveness of the company's DurAVR® Transcatheter Heart Valve against commercially available alternatives in approximately 1,000 patients. This milestone is expected to accelerate U.S. site activation and operational momentum.

04/28/2026, 6:00 AM • GlobeNewswire

Anteris Reports 2025 Financial Results and Provides Corporate Update

Anteris Technologies reported 2025 financial results with net operating cash outflows of $77.8 million, driven by increased clinical and manufacturing activities. The company initiated the global PARADIGM Trial for its DurAVR® transcatheter heart valve, received FDA IDE approval, and completed a strategic $320 million capital raise including investment from Medtronic to support commercialization efforts.

02/26/2026, 6:00 PM • GlobeNewswire

Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises

Anteris Technologies completed a $90 million strategic investment from Medtronic and a $230 million underwritten public offering, totaling $320 million in capital. The funding will support execution of the global PARADIGM trial and advance commercialization of the DurAVR® Transcatheter Heart Valve for treating aortic stenosis.

01/22/2026, 4:02 PM • GlobeNewswire

Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock

Anteris Technologies closed a $320 million capital raise consisting of a $200 million underwritten public offering of 40 million shares at $5.75 per share and a $120 million private placement to Medtronic. The company will use proceeds to advance its DurAVR® Transcatheter Heart Valve in the PARADIGM Trial, expand manufacturing capabilities, and fund research and development for v2vmedtech.

01/22/2026, 4:01 PM • GlobeNewswire

Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering

Anteris Technologies announced a $200 million public offering of 34.78 million shares at $5.75 per share, with an expected closing on January 22, 2026. Additionally, Medtronic agreed to invest up to $90 million in a private placement representing 16-19.99% ownership. Proceeds will fund the PARADIGM Trial for the DurAVR® Transcatheter Heart Valve, manufacturing expansion, and R&D for v2vmedtech.

01/20/2026, 10:53 PM • GlobeNewswire

Anteris Announces Results for the Third Quarter of 2025

Anteris Technologies received FDA approval to commence patient recruitment for its PARADIGM Trial, evaluating the DurAVR® Transcatheter Heart Valve across the United States, Europe, and Canada. The company advanced regulatory activities, strengthened operational systems, and reported $59.3 million in net operating cash outflows for the first nine months of 2025.

11/12/2025, 5:52 PM • GlobeNewswire

Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

Anteris Technologies has enrolled and treated the first patients in its global PARADIGM Trial for the DurAVR® Transcatheter Heart Valve, a study comparing the device's safety and effectiveness against existing transcatheter aortic valve replacements.

10/27/2025, 5:43 PM • GlobeNewswire

Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders

Anteris Technologies Global Corp. has adjourned its Special Meeting of Stockholders from September 18, 2025 to September 29, 2025 due to lack of quorum, allowing additional time for stockholders to vote on proposed resolutions.

09/19/2025, 2:30 AM • GlobeNewswire

Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders

Anteris Technologies Global Corp. has postponed its Special Meeting of Stockholders from September 4th to September 11th, 2025, to provide shareholders additional time to vote and facilitate broader participation.

09/04/2025, 1:42 AM • GlobeNewswire

Anteris Announces Results for the Second Quarter of 2025

Anteris Technologies reported Q2 2025 financial results, highlighting 130 patients treated with their DurAVR® Transcatheter Heart Valve, advanced preparations for the global PARADIGM Trial, and appointed two new Non-Executive Directors.

08/11/2025, 4:52 PM • GlobeNewswire